Abstract
No public abstract is available from the verified source records.
Iulia Filip
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis in low- and middle-income countries
10.1097/qad.0000000000004487 · 2026
Agreements to provide affordable lenacapavir
10.1016/j.lanmic.2025.101317 · 2026
PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women
10.1056/nejmoa2407001 · 2024
PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons
10.1056/nejmoa2411858 · 2025
Global analysis of pre-exposure prophylaxis to need ratios in 2025
10.1097/qad.0000000000004589 · 2026
Global analysis of pre-exposure prophylaxis to need ratios in 2025
10.1097/qad.0000000000004589 · doi-reference
PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons
10.1056/nejmoa2411858 · doi-reference
PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women
10.1056/nejmoa2407001 · doi-reference
Agreements to provide affordable lenacapavir
10.1016/j.lanmic.2025.101317 · doi-reference
The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis in low- and middle-income countries
10.1097/qad.0000000000004487 · doi-reference